The findings suggest that a targeted inhibitor of ALK has antitumour activity in childhood malignancies harbouring ALK translocations, particularly anaplastic large-cell lymphoma. Eight of the patients had measurable radiographic disease, six of whom had a complete response, one a partial response, and one had stable disease (table 4).